NCT06546280

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation: a Single-arm, Single-center, Exploratory Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Zhujiang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.

Detailed description

Postoperative adjuvant therapy is an important means to effectively reduce the risk of hepatocellular carcinoma recurrence and improve survival, but at this stage, there is no globally recognized postoperative adjuvant therapy for HCC. As a new first-line therapeutic agent for advanced hepatocellular carcinoma, camrelizumab plus apatinib has shown good anti-tumor efficacy in the treatment of advanced hepatocellular carcinoma in the CARES-310 study. Therefore, we wanted to explore the efficacy and safety of camrelizumab plus apatinib in adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
DRUG	Apatinib	Apatinib 250 mg will be taken orally once daily.

Timeline

• Start date: 2024-08-26
• Primary completion: 2026-08-26
• Completion: 2026-09-01
• First posted: 2024-08-09
• Last updated: 2024-08-09

Locations

1 site across 1 country: China